Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis

The incidence of intra-abdominal candidiasis is increasing, and it is now the leading indication for antifungal therapy, ahead of candidemia. Prospective randomized trials of antifungal therapy have almost exclusively concerned patients with candidemia and did not include patients with intra-abdominal infections. The aim of this study is to demonstrate that caspofungin antifungal therapy for intra-abdominal candidiasis in ICU patients is associated with lower failure rate compared to placebo.

NCT Number	NCT03580733
Lead Sponsor	Centre Hospitalier Universitaire, Amiens
Conditions	ICU Yeast Intra-abdominal Infection
Enrollment	448 participants
Start Date	2019-01-01
Primary Completion	2024-10-04 (estimated)
Study Completion	2024-12-04 (estimated)
Updated on ClinicalTrials.gov	2024-07-10